Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System

NCT ID: NCT06133647

Last Updated: 2024-01-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

8 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-04

Study Completion Date

2024-05-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Male breast cancer (MBC) is a rare disease without sufficient clinical data supporting the management and treatment. The treatment of MBC arises from data extrapolated from female breast cancer (FBC). MBC has higher mortality than FBC. Previous studies have suggested differences between MBC and FBC; however, treatments remain the same for both. Larger studies in MBC are needed to provide more clinical data to help guide treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ductal Carcinoma in Situ Invasive Lobular Breast Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

managing Male Breast Cancer Patients at Methodist Health System

To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Larger studies in MBC are needed to provide more clinical data to help guide treatment.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • ≥ 18 years of age Patients diagnosed with ductal carcinoma in situ or invasive lobular carcinoma of the breast

Exclusion Criteria

* 18 years of age

* Prisoners
* Pregnant or breastfeeding
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Methodist Health System

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Institute at Methodist Health System

Dallas, Texas, United States

Site Status RECRUITING

Clinical Research Institute at Methodist Health System

Dallas, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Colette N Ngo Ndjom, MS

Role: CONTACT

214-947-1280 ext. 74680

Kasim W Bhimani, BA

Role: CONTACT

214-947-4459 ext. 74459

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Colette N Ndjom, MS

Role: primary

410-947-4681 ext. 74681

Loretta W Bedell, MPH

Role: backup

214-947-4680 ext. 74680

Colette Ngo Ndjom, MS

Role: primary

410-947-4681 ext. 74681

Kasim A Bhimani, BA

Role: backup

214-947-4459 ext. 74459

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

015.MTP.2023.A

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.